Improving the Quality of Life of Latin American Patients
M8 provides healthcare professionals and patients with access to proven treatments they need to thrive. We serve as a comprehensive source of expertise in each of the following therapeutic areas.
Central Nervous System
- Atarax®(Hydroxyzine)
- Concerta®(Methylphenidate)
- Mokbio®(Lactobacillus plantarum 128)
- Haldol®(Haloperidol )
- Lexotan®(Bromazepam)
- Nabota®(Botulinum Toxin type A)
- Razapina®(Mirtazapina)
- Reminyl®(Galantamine Bromhide)
- Risperdal®(Risperidone)
- Seroquel®(Quetiapine)
- Sibelium®(Flunarizine)
- Topamax®(Topiramate)
- Nootropil®(Piracetam)
- Valium®(Diazepam)
- Diacomit®(Stiripentol)
Cardiometabolism
Oncology & Hematology
Reliable, Convenient Service and Support for Professionals and Patients
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Our Commitment to Latin America
Six core values guide us on our mission to provide support to the patients and healthcare professionals of Latin America.
Zestril®
Generic: Lisinopril
Description
ZESTRIL® is indicated for the treatment of arterial and renovascular hypertension, it can be used alone or in combination with other types of antihypertensive agents. ZESTRIL® is indicated for the treatment of acute myocardial infarction (within the first 24 hours) in patients who are hemodynamically stable, in order to prevent the subsequent development of left ventricular dysfunction or heart failure and improve survival. Patients should receive the recommended treatment according to their conditions, such as thrombolytics, acetylsalicylic acid, and ß-blockers.